Protocol 405-201-00013: A Phase 3 Randomized Double-blind Multicenter Placebo-controlled Parallel-group Trial Evaluating the Efficacy Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults with Attention-deficit/Hyperactivity Disorder
Brief description of study
To confirm the efficacy of centanafadine sustained-release (SR) tablets administered twice-daily (BID; 200 mg or 400 mg total daily doses [TDDs]) compared to placebo in the treatment of adults with ADHD and confirm the safety and tolerability of centanafadine SR tablets administered BID (200 mg or 400 mg TDDs) compared to placebo in the treatment of adults with ADHD. The purpose of this study is to evaluate the safety and effectiveness of an investigational drug called centanafadine sustained release (SR) for people with attention deficient hyperactivity disorder (ADHD). An investigational drug is a drug that is has not been approved by the United States Food and Drug Administration (FDA).
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
